US 9216214
Replication-competent adenoviral vectors
granted A61KA61K2039/5256A61K2039/575
Quick answer
US patent 9216214 (Replication-competent adenoviral vectors) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Dec 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K2039/5256, A61K2039/575, A61K39/21